-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: sunshine
On March 30, Connoya announced that its Class 1 new drug CM310 has achieved all efficacy endpoints and obtained positive results in its Phase II clinical study (CM310NP001) for chronic rhinosinusitis with nasal polyps
CM310 is an innovative humanized monoclonal antibody that targets human IL-4 receptor alpha subunit (IL-4Rα) independently developed by Connoya.
Source: Connoya Prospectus
CM310 is the first domestically produced IL-4Rα antibody approved by the State Food and Drug Administration for clinical trials.
CM310NP001 is a multicenter, randomized, double-blind, placebo-controlled, multiple subcutaneous phase II clinical trial to evaluate the efficacy, safety, and pharmacokinetics of CM310 in patients with chronic sinusitis and nasal polyps science, pharmacodynamics, immunogenicity
The results showed that the two primary efficacy endpoints were fully met.